- NEWS AND VIEWS
T cells engineered to target senescence
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 583, 37-38 (2020)
doi: https://doi.org/10.1038/d41586-020-01759-x
References
Amor, C. et al. Nature 583, 127–132 (2020).
Gorgoulis, V. et al. Cell 179, 813–827 (2019).
Baker, D. J. et al. Nature 530, 184–189 (2016).
Kang, T.-W. et al. Nature 479, 547–551 (2011).
Lim, W. A. & June, C. H. Cell 168, 724–740 (2017).
Curovic, V. R. et al. Diabetes Care 42, 1112–1119 (2019).
Quaglia, M., Musetti, C. & Cantaluppi, V. N. Engl. J. Med. 374, 890–891 (2016).
Wang, L. & Bernards, R. Front. Med. 12, 490–495 (2018).
Ovadya, Y. & Krizhanovsky, V. J. Clin. Invest. 128, 1247–1254 (2018).
Brudno, J. N. & Kochenderfer, J. N. Blood 127, 3321–3330 (2016).
Eggert, T. et al. Cancer Cell 30, 533–547 (2016).
Kim, K. M. et al. Genes Dev. 31, 1529–1534 (2017).
Frescas, D. et al. Proc. Natl Acad. Sci. USA 114, E1668–E1677 (2017).
Competing Interests
J.G. has acted as a consultant for Unity Biotechnology, Geras Bio and Merck KGaA; owns equity in Unity Biotechnology and Geras Bio and is a named inventor in an MRC patent related to senolytic therapies.